Notice of AGM

Summary by AI ^BETAClose X

BioPharma Credit plc has announced its 2026 Annual General Meeting will be held on June 17, 2026, at 1:00 p.m. at Herbert Smith Freehills LLP in London. This follows the release of the Company's Annual Financial Report for the year ended December 31, 2025, on March 24, 2026. The notice of the AGM is available on the company's website and has been submitted to the National Storage Mechanism.

Disclaimer*

BioPharma Credit PLC

06 May 2026

6 May 2026

BioPharma Credit plc

(the "Company")

NOTICE OF ANNUAL GENERAL MEETING

Following the publication of the Company's Annual Financial Report for the year ended 31 December 2025 on 24 March 2026, the Company announces that it will hold its 2026 Annual General Meeting ("AGM") at 1.00 p.m. on 17 June 2026 at the offices of Herbert Smith Freehills LLP, Exchange House, Primrose Street, London EC2A 2EG.

A copy of the Notice of the AGM is available to view on the Company's website at https://bpcruk.com/investor-materials/. It has also been submitted to the National Storage Mechanism and is available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. Copies of the Notice of the AGM have been posted or made available to the Company's Shareholders.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Henry Wilson / Helen Tarbet /Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END